CURE

FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
Fierce Pharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...

Merck wins FDA approval for subcutaneous Keytruda: Endpoints

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its’s blockbuster cancer drug, ...
News-Medical.Net on MSN

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective ...